GLP-1 Agonist Therapy Center

GLP-1 drug shows potential to treat both diseases… Nonalcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease in America which affects approximately 30% of the population, is known to contribute to prediabetes and diabetes due to the liver’s important role in the regulation of blood sugar …

Adult offspring of mothers who had GDM or type 1 diabetes during pregnancy showed lower levels of fasting GLP-1 and weakened glucagon suppression… Louise Kepstrup, MD, of Copenhagen University Hospital in Denmark, and colleagues in the follow-up study, evaluated data on adult children (aged 18-27 years) from all pregnancies complicated …

Researchers compared glucose and hormonal responses to a liquid meal test in 20 obese participants with T2 who underwent RYGB or nonsurgical intensive lifestyle modification… Rapid glycemic improvements following Roux-en-Y gastric bypass (RYGB) are frequently attributed to the enhanced GLP-1 response, but causality remains unclear. To determine the role of …

This might be a reason not to use a DPP-4 for those with long standing diabetes… Reduction in the glucose-regulating hormone glucagon-like peptide-1 (GLP-1) appears to occur before the development of type 2 diabetes and obesity, according to new published research. Investigator Kristine Færch, PhD, senior research fellow at the …

Glucose-dependent insulinotropic polypeptide and glucagon- like peptide-1 have glucose-dependent effects on glucagon secretion but differ in their effects on type 1 and type 2 diabetes patients… From various studies we know that glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have glucose-dependent effects on glucagon secretion. GIP causes increased glucagon …

Glucose regulation and weight management are very important factors when treating type 2 diabetes patients… Prior studies have shown that glucagon-like peptide receptor agonist are beneficial not only for better glucose control but also helpful in weight reduction in patients with type 2 diabetes. Other studies and recommendations on type …

Endogenous glucagon-like peptide-1 (GLP-1) agonists appears to inhibit fluid intake… Type 2 patients have an elevated risk for dehydration due to high glucose levels, and an increasingly popular class of diabetes drugs may increase this risk even more, a team of researchers at the State University of New York at …

Study shows decrease in food intake and food-related brain responses… GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. Researchers hypothesized that food intake reduction after GLP-1 receptor activation is mediated …

  ITCA 650 A 1 year implant dose of exenatide in type 2 diabetes shows positive results. See item #6 for more information.             See more GLP-1 Agonist Resources

Phase 3 trial demonstrates the safety and efficacy of albiglutide in type 2 diabetes patients with renal impairment…. Renal impairment is a common comorbid condition in type 2 diabetes patients with reported incidence rates as high as 35%. Those with renal insufficiency often find their diabetes treatment options limited. Possible …